MTNB (Matinas BioPharma Holdings) Earnings per share for the last four quarters

Matinas BioPharma Holdings Inc. (MTNB) - corporate logo

Matinas BioPharma is protected by the LNC patent system and strict FDA oversight. However, business success relies on partnership contracts, where the risk of failed tests remains significant. Current development is supported by investments, as the stage of commercial cash inflow has not yet been reached. This chart of net income per share YoY ttm confirms these data, with the indicator holding at 69.40.

MTNB matinasbiopharma.com Net earnings per share (EPS TTM) (02/11/2024 - 11/16/2026)

MTNB (matinasbiopharma.com): analytical breakdowns and indicator data

Fundamental company valuation:MTNB (Matinas BioPharma Holdings Inc.)
Core merchandise of Matinas BioPharma

Investors are assessing the potential of Matinas BioPharma (MTNB) through the dynamics of real earnings per share. This metric measures the annual percentage growth of net income (TTM), reflecting the efficiency of asset monetization. By analyzing the historical EPS YoY (TTM) percentage growth, one can track the impact of LNC technology implementation partnerships on financial results. A positive trend confirms the commercial value of the drug delivery ecosystem; however, earnings growth must be weighed against the stock's market valuation.

Competitor analysis

Net earnings per one share for the last twelve months Ascendis Pharma Inc.|MDGL (Madrigal Pharmaceuticals, Inc.) - Net earnings per share for the last 12 months|CORT: Earnings per share for the last four quarters|RYTM (Rhythm Corp) - Net earnings per share (EPS TTM)|Net earnings per share (EPS TTM) Akero Therapeutics|Net earnings per share (EPS TTM) MTSR|Earnings per share for the last twelve months MLTX (MoonLake Immunotherapeutics AG)|Earnings per share for the last twelve months crinetics.com CRNX|NewAmsterdam Pharma Corp (NAMS) - Net earnings per one share for the last twelve months|SLNO - Earnings per share for the last twelve months|FOLD: Earnings per share for the last twelve months|ETNB: Net earnings per share (EPS TTM)|AGIO - Net earnings per share for the last four quarters|Earnings per share for the last twelve months Structure Corp|MiMedx Corp (MDXG) - Net earnings per share for the last four quarters|Earnings per share for the last twelve months rezolutebio.com (RZLT)|Net earnings per share for the last 12 months lexpharma.com LXRX|Net earnings per share (EPS TTM) MBX (MBX Biosciences)|Altimmune Corp - Earnings per share for the last twelve months|Aardvark Therapeutics Inc. - Net earnings per share (EPS TTM)|SGMT - Net earnings per share (EPS TTM)|BioAge Labs (BIOA) - Earnings per share for the last twelve months|Net earnings per one share for the last twelve months biomeafusion.com (BMEA)|Earnings per share for the last twelve months Quince Therapeutics, Inc.|Net earnings per share for the last 12 months Fractyl (GUTS)|Net earnings per share for the last 12 months VTVT (vTv Therapeutics Inc.)|ATPC - Net earnings per one share for the last twelve months|Pluri Inc. - Net earnings per share for the last 12 months|Net earnings per share for the trailing year Synlogic Corp|LPCN - Earnings per share for the last twelve months|Earnings per share for the trailing year SPRB (Spruce Biosciences)|GLTO (Galecto Corp) - Net earnings per share for the last 12 months|Carmell Corp - Earnings per share for the trailing year|LUMO (Lumos Therapeutics) - Net earnings per share (EPS TTM)|ONVO: Earnings per share for the trailing year|Net earnings per share (EPS TTM) RDUS